Journal: Future oncology (London, England)
Pirtobrutinib is a novel noncovalent BTK inhibitor designed to overcome resistance caused by BTK mutations, particularly the C481S mutation. This mutation limits the efficacy of current covalent BTK inhibitors like ibrutinib, acalabrutinib, and zanubrutinib.
Its unique binding mechanism allows pirtobrutinib to retain activity in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL) who have developed resistance to standard BTK inhibitors.
Clinical data support its effectiveness in this setting, and ongoing studies are evaluating:
- Use in combination therapies
- Earlier treatment lines